Tumor necrosis factor (TNF)-α and TNF receptors in viral pathogenesis

Proceedings of the Society for Experimental Biology and Medicine

Volumn 223, Issue 3, 2000, Pages 241-257

  Herbein, Georges ^a   O'Brien, William A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS PROTEIN;

CELL DIFFERENTIATION; CELL VIABILITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; LIGAND BINDING; SHORT SURVEY; SIGNAL TRANSDUCTION; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 0034115960     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1373.2000.22335.x     Document Type: Short Survey

References (196)

1. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YCE, Mathison J, Ulevitch R, Cerami A. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552-554, 1985.
2. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320:584-588, 1986.
3. Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 9:28-31, 1988.
4. Beutler B, Van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 264:667-668, 1994.
5. Bazzoni F, Beutler B. How do tumor necrosis factor receptors work? J Inflamm 45:221-238, 1995.
6. Hodge-Dufour J, Marino MW, Horton MR, Jungbluth A, Burdick MD, Strieter RM, Noble PW, Hunter CA, Pure A. Inhibition of interferon-γ-induced interleukin 12 production: A potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc Natl Acad Sci U S A 95:13806-13811, 1998.
7. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO. Chronic tumor necrosis factor alters T-cell responses by attenuating T-cell receptor signaling. J Exp Med 185:1573-1584, 1997.
8. Hohmann HP, Remy R, Brockhaus M, van Loon AP. Two different cell types have different major receptors for human tumor necrosis factor (TNF-α). J Biol Chem 264:14927-14934, 1989.
9. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 87:3127-3131, 1990.
10. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor: Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem 266:18846-18853, 1991.
11. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 95:570-575, 1998.
12. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80-kDa tumor necrosis factor receptor. Cell 83:793-802, 1995.
13. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 268:18542-18548, 1993.
14. Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 28:257-263, 1998.
15. Haridas V, Darnay BG, Natarajan K, Heller R, Aggarwal BB. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-κB activation, and c-Jun kinase activation. J Immunol 160:3152-3162, 1998.
16. Espevik T, Brockhaus M, Loetscher H, Nonstad U, Shalaby R. Characterization of binding and biological effects of monoclonal antibodies against human tumor necrosis factor receptor. J Exp Med 171:415-426, 1990.
17. Wiegmann K, Schutze S, Kampen E, Himmler A, Machleidt T, Kronke M. Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J Biol Chem 267:17997-18001, 1992.
18. Weiss T, Grell M, Siemienski K, Muhlenbeck F, Durkop H, Pfizenmaier K, Scheurich P, Wajant H. TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol 161:3136-3142, 1998.
19. Gehr G, Gentz R, Brockhaus M, Loetscher H, Lesslauer W. Both tumor necrosis factor receptors mediate proliferative signals in human mononuclear cell activation. J Immunol 149:911-917, 1992.
20. Vandenabeele P, Declercq W, Van Vercammen D, de Craen M, Grooten J, Loetscher H, Brockhaus M, Lesslauer W, Fiers W. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T-cell hybridoma. J Exp Med 176:1015-1024, 1992.
21. Jacobsen FW, Rothe M, Rusten L, Goeddel DV, Smeland EB, Veiby OP, Slordali L, Jacobsen SEW. Role of the 75-kDa tumor necrosis factor (TNF) receptor: Inhibition of early hematopoiesis. Proc Natl Acad Sci U S A 91:10695-10699, 1994.
22. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348-351, 1995.
23. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608, 1993.
24. Lin RH, Hwang YW, Yang BC, Lin CS. TNF receptor 2-triggered apoptosis is associated with the downregulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. J Immunol 158:598-603, 1997.
25. Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka D, Holtmann H, Wallach D. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269-3278, 1990.
26. Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor-α inhibitor. J Biol Chem 264:11966-11973, 1989.
27. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, Hadas E, Leitner O, Wallach D. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265:14497-14504, 1990.
28. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218-220, 1994.
29. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329, 1992.
30. Gatanaga T, Hwang CD, Gatanaga M, Cappuccini F, Yamamoto RS, Granger GA. The regulation of TNF receptor mRNA synthesis, membrane expression, and release by PMA- and LPS-stimulated human monocytic THP-1 cells in vitro. Cell Immunol 138:1-10, 1991.
31. Leeuwenberg JF, Dentener MA, Buurman WA. Lipopolysaccharide (LPS)-mediated soluble TNF receptor release and TNF receptor expression by monocytes: Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. J Immunol 152:5070-5076, 1994.
32. Kalinkovich A, Engelmann H, Harpaz N, Burstein R, Barak V, Kalickman I, Wallach D, Bentwich Z. Elevated serum levels of soluble tumour necrosis factor receptors (sTNFR) in patients with HIV infection. Clin Exp Immunol 89:351-355, 1992.
33. Hober D, Benyoucef S, Delannoy AS, de Groote D, Ajana F, Mouton Y, Wattre P. High plasma level of soluble factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients. Infection 24:213-217, 1996.
34. Nokta M, Rossero R, Loesch K, Pollard RB. Kinetics of tumor necrosis factor-α and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didnosine, and hydroxyurea. AIDS Res Hum Retroviruses 13:1633-1638, 1997.
35. Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, Hornik V, Levo Y, Maini RN, Feldmann M. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 36:1111-1120, 1993.
36. Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis, and osteoarthritis. Clin Exp Immunol 92:19-22, 1993.
37. Lazdins JK, Grell M, Walker MR, Woods-Cook K, Scheurich P, Pfizenmaier K. Membrane tumor necrosis factor (TNF)- induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells. J Exp Med 185:81-90, 1997.
38. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MAJ, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A 88:9292-9296, 1991.
39. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782-784, 1996.
40. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 274:784-787, 1996.
41. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274:787-789, 1996.
42. Roulston A, Reinhard C, Amiri P, Williams LT. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor-α. J Biol Chem 273:10232-10239, 1998.
43. Gruss HJ, Dower SK. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther 1:75-105, 1995.
44. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81:495-504, 1995.
45. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:1243-1252, 1995.
46. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299-308, 1996.
47. Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J 15:6189-6196, 1996.
48. Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME, Dixit VM. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 271:4961-4965, 1996.
49. Varfolomeev E, Boldin M, Goncharov T, Wallach D. A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor and Fas/APO1: Proteins binding to the death domains of the two receptors also bind to each other. J Exp Med 183:1271-1275, 1996.
50. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95, and IL-1. Nature 385:540-544, 1997.
51. Regnier CH, Songt HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an I-κB kinase. Cell 90:373-383, 1997.
52. DiDonato JA, Hayakawa M, Rothwharf DM, Zandi E, Karin M. A cytokine-responsive I-κB kinase that activates the transcription factor NF-κB. Nature 388:548-554, 1997.
53. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A. IKK-1 and IKK-2: Cytokine-activated I-κB kinases essential for NF-κB activation. Science 278:860-866, 1997.
54. Zandi E, Rothwarf DM, Delhare M, Hayakawa M, Karin M. The I-κB kinase (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for I-κB phosphorylation and NF-κB activation. Cell 91:243-252, 1997.
55. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV. I-κB kinase-β: NF-κB activation and complex formation with I-κB kinase-α and NIK. Science 278:866-869, 1997.
56. Liu ZG, Hsu H, Goeddel D, Karin M. Dissection of TNF-receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87:565-576, 1996.
57. Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, Levrero M. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF-2-dependent pathway. Science 275:200-203, 1997.
58. Song H, Regnier C, Kirschning C, Goeddel D, Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: Bifucation of nuclear factor-κB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A 94:9792-9796, 1997.
59. Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, de la Pompa JL, Ferrick D, Hum B, Iscove N, Ohashi P, Rothe M, Goeddel DV, Mak TW. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 7:715-725, 1997.
60. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity 7:703-713, 1997.
61. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8:297-303, 1998.
62. Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A 93:13973-13978, 1996.
63. Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV, Mak TW. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:1954-1958, 1998.
64. Duan H, Dixit VM. RAIDD is a new "death" adapter molecule. Nature 385:86-89, 1997.
65. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 283:543-546, 1999.
66. Sing A, Ni J, Aggarwal BB. Death domain receptors and their role in cell demise. J Interferon Cytokine Res 18:439-450, 1998.
67. Salvesen GS, Dixit VM. Caspases: Intracellular signaling by proteolysis. Cell 91:443-146, 1997.
68. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ. Ordering the cytochrome-c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144:281-292, 1999.
69. Green DR, Reed JC. Mitochondria and apoptosis. Science 281:1309-1312, 1998.
70. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 281:1312-1316, 1998.
71. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 18:2967-2987, 1999.
72. Schreiber M, Rajarathnam K, McFadden G. Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNF-α, but the dimer is a more potent TNF inhibitor. J Biol Chem 271:13333-13341, 1996.
73. Schreiber M, Sedger L, McFadden G. Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol 71:2171-2181, 1997.
74. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM, Salvesen GS. Target protease specificity of the viral serpin CrmA: Analysis of five caspases. J Biol Chem 272:7797-7800, 1997.
75. Kettle S, Alcami A, Khanna A, Ehret R, Jassoy C, Smith GL. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1β-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J Gen Virol 78:677-685, 1997.
76. Paulose M, Bennett BL, Manning AM, Essani K. Selective inhibition of TNF-α induced cell adhesion molecule gene expression by tanapox virus. Microb Pathog 25:33-41, 1998.
77. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A 94:1447-1452, 1997.
78. Sylla BS, Hung SC, Davidson DM, Hatzivassiliou E, Malinin NL, Wallach D, Gilmore TD, Kieff E, Mosialos G. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the I-κB kinases IKK-α and IKK-β. Proc Natl Acad Sci U S A 95:10106-10111, 1998.
79. Devergne O, McFarland EC, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 72:7900-7908, 1998.
80. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1l engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-399, 1995.
81. Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol 71:4649-1656, 1997.
82. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A 93:11085-11090, 1996.
83. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 17:1700-1709, 1998.
84. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338:1413-1421, 1998.
85. Kawanishi M. Epstein-Barr virus BHRF1 protein protects intestine 407 epithelial cells from apoptosis induced by tumor necrosis factor-α and anti-Fas antibody. J Virol 71:3319-3322, 1997.
86. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-α gene by Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 100:1969-1979, 1997.
87. Rossol-Voth R, Rossol S, Schutt KH, Corridori S, de Cian W, Falke D. In vivo protective effect of tumour necrosis factor-α against experimental infection with herpes simplex virus type 1. J Gen Virol 72:143-147, 1991.
88. Delero GC, Marcatili A, Folgere A, Donnarumma G, Petrillo G. TNF-α expression and herpes simplex infection in human monocytes treated with growth hormone, prolactin, and insulin. Microbiologica 21:213-220, 1998.
89. Galvan V, Brandimarti R, Roizman B. Herpes simplex virus 1 blocks caspase-3-independent and caspase-dependent pathways to cell death. J Virol 73:3219-3226, 1999.
90. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427-436, 1996.
91. Whitbeck JC, Peng C, Lou H, Xu R, Willis SH, Ponce de Leon M, Peng T, Nicola AV, Montgomery RI, Warner MS, Soulika AM, Spruce LA, Moore WT, Lambris JD, Spear PG, Cohen GH, Eisenberg RJ. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol 71:6083-6093, 1997.
92. Terry-Allison T, Montgomery RI, Whitbeck JC, Xu R, Cohen GH, Eisenberg RJ, Spear PG. HveA (herpesvirus entry mediator A), a co-receptor for herpes simplex virus entry, also participates in virus-induced cell fusion. J Virol 72:5802-5810, 1998.
93. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. J Biol Chem 272:14029-14032, 1997.
94. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, Ruben S, Murphy M, Eisenberg RJ, Cohen GH, Spear PG, Ware CF. LIGHT, a new member of the TNF superfamily, and lymphotoxin-α are ligands for herpesvirus entry mediator. Immunity 8:21-30, 1998.
95. Stein J, Volk HD, Liebenthal C, Kruger DH, Frosch S. Tumour necrosis factor-α stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol 74:2333-2338, 1993.
96. Geist LJ, Monick MM, Stinski MF, Hunninghake GW. The immediate early genes of human cytomegalovirus upregulate tumor necrosis factor-α gene expression. J Clin Invest 93:474-478, 1994.
97. Smith PD, Saini SS, Raffeld M, Manischewitz JF, Wahl SM. Cytomegalovirus induction of tumor necrosis factor-α by human monocytes and mucosal macrophages. J Clin Invest 90:1642-1648, 1992.
98. + T-cell clones specifically activated by IE1 peptides in vitro. J Virol 70:2162-2169, 1996.
99. Lucin P, Jonjic S, Messerle M, Polic B, Hengel H, Koszinowski UH. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-γ and tumour necrosis factor. J Gen Virol 75:101-110, 1994.
100. Yerkovich ST, Olver SD, Lenzo JC, Peacock CD, Price P. The roles of tumour necrosis factor-α, interleukin-1, and interleukin-12 in murine cytomegalovirus infection. Immunology 91:45-52, 1997.
101. Pavic I, Polic B, Crnkovic I, Lucin P, Jonjic S, Koszinowski UH. Participation of endogenous tumour necrosis factor-α in host resistance to cytomegalovirus infection. J Gen Virol 74:2215-2223, 1993.
102. Orange JS, Salazar-Mather TP, Opal SM, Biron CA. Mechanisms for virus-induced liver disease: Tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol 71:9248-9258, 1997.
103. Lee H, Choi JK, Li MT, Kaye K, Kieff E, Jung JU. Role of cellular tumor necrosis factor receptor-associated factors in NF-κB activation and lymphocyte transformation by herpesvirus Saimiri STP. J Virol 73:3913-3919, 1999.
104. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor-α. Proc Natl Acad Sci U S A 94:8744-8749, 1997.
105. Lara-Pezzi E, Mesilla AL, Majano PL, Redondo JM, Lopez-Cabrera M. The hepatitis B virus X protein activates nuclear factor of activated T cells (NF-AT) by a cyclosporin A-sensitive pathway. EMBO J 17:7066-7077, 1998.
106. Fang JW, Shen WW, Meager A, Lau JY. Activation of the tumor necrosis factor-α system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol 91:748-753, 1996.
107. Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I, Oldstone MB, Chisari FV. Viral cross talk: Intracellular activation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A 93:4589-4594, 1996.
108. Guidotti LG, Borrow P, Brown A, McClary H, Koch R, Chisari FV. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J Exp Med 189:1555-1564, 1999.
109. Guidotti LG, Rochford R, Chung J, Shapiro M, Purecll R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829, 1999.
110. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenefelde KH, Rittner C. A tumor necrosis factor-α (TNF-α) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 111:579-582, 1998.
111. Lopez-Guerrero JA, Rayet B, Tuynder M, Rommelaere J, Dinsart C. Constitutive activation of U937 promonocytic cell clones selected for their resistance to parvovirus H-1 infection. Blood 89:1642-1653, 1997.
112. Rayet B, Lopez-Guerrero JA, Rommelaere J, Dinsart C. Induction of programmed cell death by parvovirus H-1 in U937 cells: Connection with the tumor necrosis factor-α signaling pathway. J Virol 72:8893-8903, 1998.
113. Gomez del Moral M, Ortuno E, Fernandez-Zapatero P, Alonso F, Alonso C, Ezquerre A, Dominguez J. African swine fever virus infection induces tumor necrosis factor-α production: Implications in pathogenesis. J Virol 73:2173-2180, 1999.
114. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 262:1011-1018, 1993.
115. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 85:289-291, 1988.
116. Herbein G, Montaner LJ, Gordon S. Tumor necrosis factor-α inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: A selective role for the 75-kDa receptor. J Virol 70:7388-7397, 1996.
117. Rarsten V, Gordon S, Kirn A, Herbein G. HIV-1 envelope glycoprotein gp120 downregulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor-α. Immunology 88:55-60, 1996.
118. Herbein G, Doyle AG, Montaner LJ, Gordon S. Lipopolysaccharide (LPS) downregulates CD4 expression in primary human macrophages through induction of endogenous tumor necrosis factor (TNF) and IL-1β. Clin Exp Immunol 102:430-437, 1995.
119. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187:875-883, 1998.
120. Schmidtmayerova H, Nottet HS, Nuovo G, Raabe T, Flanagan CR, Dubrovsky L, Gendelman HE, Cerami A, Bukrinsky M, Sherry B. Human immunodeficiency virus type 1 infection alters chemokine-β peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A 93:700-704, 1996.
121. DiMarzio P, Tse J, Landau NR. Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Res Hum Retroviruses 14:129-138, 1998.
122. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W. Human tumor necrosis factor-α (TNF-α) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 268:26350-26357, 1993.
123. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor-α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc Natl Acad Sci U S A 86:5974-5978, 1989.
124. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor-α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor-ιB. Proc Natl Acad Sci U S A 86:2336-2340, 1989.
125. Poli G, Kinter A, Justement S, Kebrl JH, Bressler P, Stanley S, Fauci AS. Tumor necrosis factor-α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A 87:782-785, 1990.
126. Butera ST, Roberts BD, Leung K, Nabel GJ, Folks TM. Tumor necrosis factor receptor expression and signal transduction in HIV-1 infected cells. AIDS 7:911-918, 1993.
127. Herbein G, Gordon S. 55- and 75-kDa tumor necrosis factor receptors mediate distinct actions in regard to human immunodeficiency virus type 1 replication in primary human macrophages. J Virol 71:4150-4156, 1997.
128. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 276:1857-1861, 1997.
129. Zybarth G, Reiling N, Schmidtmayerova H, Sherry B, Bukrinsky M. Activation-induced resistance of human macrophages to HIV-1 infection m vitro. J Immunol 162:400-406, 1999.
130. Alfano M, Schmidtmayerova H, Bukrinsky M. Bacterial lipopolysaccharide is a potent inhibitor of HIV-1 replication in T lymphocytes and macrophages. AIDS 12:1724-1726, 1998.
131. Margolick JB, Munoz A, Donnenberg AD, Park LP, Galai N, Giorgi JV, O'Gorman MR, Ferbas J. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection: The Multiple AIDS Cohort Study. Nat Med 1:674-680, 1995.
132. + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395:189-194, 1998.
133. Herbein G, Van Lint C, Lovett JL, Verdin E. Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes. J Virol 72:660-670, 1998.
134. Yu XF, Wang Z, Vlahov D, Markham RB, Farzadegan H, Margolick JB. Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T-cell decline and disease progression in injection drug users. J Infect Dis 178:388-396, 1998.
135. Somasundaran M, Robinson HL. A major mechanism of human immunodeficiency virus-induced cell killing does not involve cell fusion. J Virol 61:3114-3119, 1987.
136. + T cells by a Fas-independent mechanism. J Exp Med 187:1113-1122, 1998.
137. Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG. AIDS retrovirus induced cytopathology: Giant cell formation and involvement of CD4 antigen. Science 232:1123-1127, 1986.
138. Sodroski J, Goh WC, Rosen C, Tartar A, Portetelle D, Burny A, Haseltine W. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 231:1549-1553, 1986.
139. + lymphocytes and cells infected by human immunodeficiency virus. Proc Natl Acad Sci U S A 84:1429-1433, 1987.
140. Golding H, Robey FA, Gates FT III, Linder W, Beining PR, Hoffman T, Golding B. Identification of homologous regions in human immunodeficiency virus 1 gp41 and human MHC class II β1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med 167:914-923, 1988.
141. Zinkernagel RM, Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS. Immunol Today 15:262-268, 1994.
142. Imberti L, Sottini A, Bettinardi A, Puoti M, Primi D. Selective depletion in HIV infection of T cells that bear specific T-cell receptor Vβ sequences. Science 254:860-862, 1991.
143. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis. Immunol Today 12:102-105, 1991.
144. Laurent-Crawford AG, Krust B, Muller S, Riviere Y, Rey-Cuille MA, Bechet JM, Montagnier L, Hovanessian AG. The cytopathic effect of HIV is associated with apoptosis. Virology 185:829-839, 1991.
145. + T cells in vitro: Differential induction of apoptosis in these cells. J Immunol 152:330-342, 1994.
146. Terai C, Kornbluth RS, Pauza CD, Richman DD, Carson DA. Apoptosis as a mechanism of cell death in culture T lymphoblasts acutely infected with HIV-1. J Clin Invest 87:1710-1715, 1991.
147. Gougeon ML, Garcia S, Heeney J, Tschopp R, Lecoeur H, Guetard D, Rame V, Dauguet C, Montagnier L. Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses 9:553-563, 1993.
148. + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 175:331-340, 1992.
149. + T cells from HIV-infected persons. J Immunol 153:412-420, 1994.
150. Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanaraman VS, Pahwa S. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type 1-infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 82:3392-3400, 1993.
151. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1:129-134, 1995.
152. Badley AD, McEhlinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 70:199-206, 1996.
153. + T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 185:55-64, 1997.
154. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion. Blood 84:2622-2631, 1994.
155. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682, 1995.
156. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690, 1996.
157. Lewis DE, Ng Tang DS, Wang X, Kozinetz C. Co-stimulatory pathways mediate monocyte-dependent lymphocyte apoptosis in HIV. Clin Immunol 90:302-312, 1999.
158. Ameisen JC. Setting death in motion. Nature 395:117-119, 1998.
159. Ray RB, Meyer K, Steele R, Shrivastava A, Aggarwal BB, Ray R. Inhibition of tumor necrosis factor (TNF-α)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 273:2256-2259, 1998.
160. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor α-mediated apoptosis via NF-kB activation. J Virol 73:4713-4720, 1999.
161. You LR, Chen CM, Lee YHW. Hepatitis C virus core protein enhances NF-κB signal pathway triggering by lymphotoxin-β receptor ligand and tumor necrosis factor-α. J Virol 73:1672-1681, 1999.
162. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C, Lai MM. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 72:3691-3697, 1998.
163. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY. Activation of tumor necrosis factor-α system in chronic hepatitis C virus infection. Digestive Dis Sci 42:2487-2494, 1997.
164. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MW, Rossol S. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111:269-277, 1998.
165. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. Tumor necrosis factor-α promoter polymorphism at position 238 is associated with chronic active hepatitis C infection. J Med Virol 54:173-177, 1998.
166. Roberts NJ Jr., Nichols JE. Regulation of lymphocyte proliferation after influenza virus infection of human mononuclear leukocytes. J Med Virol 27:179-187, 1989.
167. Mock DJ, Roberts NJ Jr. Role of the monocyte-macrophage in influenza virus infection of lymphocytes: Implication for HIV infection. AIDS Res Hum Retroviruses 6:965-966, 1990.
168. Hofmann P, Sprenger H, Kaufmann A, Bender A, Hasse C, Nain M, Gemsa D. Susceptibility of mononuclear phagocytes to influenza A virus infection and possible role in the antiviral response. J Leukoc Biol 61:408-414, 1997.
169. Sareneva T, Matikainen S, Kurimoto M, Julkunen I. Influenza A virus-induced IFN-α/β and IL-18 synergistically enhance IFN-γ gene expression in human T cells. J Immunol 160:6032-6038, 1998.
170. Gong JH, Sprenger H, Hinder F, Bender A, Schmidt A, Horch S, Nain M, Gemsa D. Influenza A virus infection of macrophages: Enhanced tumor necrosis factor-α (TNF-α) gene expression and lipopolysaccharide-triggered TNF-α release. J Immunol 147:3507-3513, 1991.
171. Lehmann C, Sprenger H, Nain M, Bacher M, Gemsa D. Infection of macrophages by influenza A virus: Characteristics of tumour necrosis factor-α (TNF-α) gene expression. Res Virol 147:123-130, 1996.
172. Nain M, Hinder F, Gong JH, Schmidt A, Bender A, Sprenger H, Gemsa D. Tumor necrosis factor-α production of influenza A virus-infected macrophages and potentiating effect of lipopolysaccharide. J Immunol 145:1921-1928, 1990.
173. Bender A, Amann U, Jager R, Nain M, Gemsa D. Effect of granulocyte/macrophage colony-stimulating factor on human monocytes infected with influenza A virus: Enhancement of virus replication, cytokine release, and cytotoxicity. J Immunol 151:5416-5424, 1993.
174. Brown EL, Wooters JL, Ferenz CR, O'Brien CM, Hewick RM, Herrmann SH. Characterization of peptide binding to the murine MHC class I H-2Kk molecule: Sequencing of the bound peptides and direct binding of synthetic peptides to isolated class I molecules. J Immunol 153:3079-3092, 1994.
175. + influenza virus-specific CTL clone. Viral Immunol 6:1-11, 1993.
176. Van Campen H. Influenza A virus replication is inhibited by tumor necrosis factor-α in vitro. Arch Virol 136:439-446, 1994.
177. Pahl HL, Baeuerle PA. Expression of influenza virus hemagglutinin activates transcription factor NF-κB. J Virol 69:1480-1484, 1995.
178. Becker S, Quay J, Soukup J. Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol 147:4307-4312, 1991.
179. Cirino NM, Panuska JR, Villani A, Taraf H, Rebert NA, Merolla R, Tsivitse P, Gilbert IA. Restricted replication of respiratory syncytial virus in human alveolar macrophages. J Gen Virol 74:1527-1537, 1993.
180. Arnold R, Konig B, Galatti H, Werchau H, Konig W. Cytokine (IL-8, IL-6, TNF-α) and soluble TNF receptor-1 release from human peripheral blood mononuclear cells after respiratory syncytial virus infection. Immunology 85:364-372, 1995.
181. Patel JA, Jiang Z, Nakajima N, Kunimoto M. Autocrine regulation of interleukin-8 by interleukin-1α in respiratory syncytial virus-infected pulmonary epithelial cells in vitro. Immunology 95:501-506, 1998.
182. Jiang Z, Kunimoto M, Patel JA. Autocrine regulation and experimental modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus. J Virol 72:2496-2499, 1998.
183. Panuska JR, Merolla R, Rebert NA, Hoffmann SP, Tsivitse P, Cirino NM, Silverman RH, Rankin JA. Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages: Suppression of early cytokine production and implications for incomplete immunity. J Clin Invest 96:2445-2453, 1995.
184. Fiedler MA, Wernke-Dollries K. Incomplete regulation of NF-κB by I-κBα during respiratory syncytial virus infection in A549 cells. J Virol 73:4502-4507, 1999.
185. Jamaluddin M, Casola A, Garofalo RP, Han Y, Elliott T, Ogra PL, Brasier AR. The major component of I-κBα proteolysis occurs independently of the proteosome pathway in respiratory syncytial virus-infected pulmonary epithelial cells. J Virol 72:4849-4857, 1998.
186. Langedijk JP, de Groot BL, Berendsen HJ, van Oirschot JT. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology 243:293-302, 1998.
187. Finke D, Brinckmann UG, ter Meulen V, Liebert UG. γ-Interferon is a major mediator of antiviral defense in experimental measles virus-induced encephalitis. J Virol 69:5469-5474, 1995.
188. Massa PT, Schimpl A, Wecker E, ter Meulen V. Tumor necrosis factor amplifies measles virus-mediated Ia induction on astrocytes. Proc Natl Acad Sci U S A 84:7242-7245, 1987.
189. Dhib-Jalbut SS, Cowan EP. Direct evidence that interferon-β mediates enhanced HLA-class I expression in measles virus-infected cells. J Immunol 151:6248-6258, 1993.
190. Dhib-Jalbut SS, Xia Q, Drew PD, Swoveland PT. Differential upregulation of HLA class I molecules on neuronal and glial cell lines by virus infection correlates with differential induction of IFN-β. J Immunol 155:2096-2108, 1995.
191. Dhib-Jalbut S, Xia J, Rangaviggula H, Fang YY, Lee T. Failure of measles virus to activate nuclear factor-κB in neuronal cells: Implications on the immune response to viral infections in the central nervous system. J Immunol 162:4024-4029, 1999.
192. Wong GHW, Goeddel DV. Tumour necrosis factor-α and β inhibit virus replication and synergize with interferons. Nature 323:819-822, 1986.
193. Koyama AH, Arakawa T, Adachi A. Acceleration of virus-induced apoptosis by tumor necrosis factor. FEBS Lett 426:179-182, 1998.
194. + cytotoxic T lymphocyte clones. J Virol 73:3623-3629, 1999.
195. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J Infect Dis 179:S188-S191, 1999.
196. Ryabchikova E, Kolesnikova L, Smolina M, Tkachev V, Pereboeva L, Baranova S, Grazhdantseva A, Rassadkin Y. Ebola virus infection in guinea pigs: Presumable role of granulomatous inflammation in pathogenesis. Arch Virol 141:909-921, 1996.